87th European Atherosclerosis Society Congress
- Date: 27 May 2019
- Location: Maastricht, Netherlands
During the 87th European Atherosclerosis Society Congress in Maastricht, Netherlands, the company will present a combined analysis of data in renal-impaired patients from ORION-1 and ORION-7 during an oral abstract session on May 27, 2019. Data in homozygous familial hypercholesterolemia patients from ORION-2 will be presented during a late-breaking abstract session on the same day.
- ORION-1 is a Phase 2, placebo-controlled, double-blind, randomized trial to evaluate the efficacy, safety, and tolerability of inclisiran in participants with ASCVD or ASCVD-risk equivalents and elevated LDL-C despite maximum tolerated dose of LDL-C lowering therapies.
- ORION-7 is a Phase 1, single-dose, open-label trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of inclisiran in participants with mild, moderate, and severe renal impairment compared to participants with normal renal function.
- ORION-2 is a Phase 2 pilot study to assess the safety, tolerability, and efficacy of inclisiran in participants with homozygous familial hypercholesterolemia.